Industries > Pharma > Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2019-2029

Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2019-2029

Aminosalicylates, Antibiotics, Corticosteroids, Immunomodulators, Biologics, Crohn’s Disease, Ulcerative Colitis, Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

PUBLISHED: 21 June 2019
PAGES: 245
PRODUCT CODE: PHA0441
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
SKU: PHA0441 Categories: , Tags: , , , ,

The global inflammatory bowel diseases (IBD) drug market is estimated at $7.2bn in 2018. Biologic therapies held 65% share of the IBD market in 2018 and is estimated to grow at a CAGR of 3.6% in the first half of the forecast period.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 245-page report you will receive 119 tables and 77 figures– all unavailable elsewhere.

The 245-page report provides clear detailed insight into the global inflammatory bowel diseases (IBD) drug market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Global Inflammatory Bowel Diseases (IBD) Drug Market forecasts from 2019-2029

• Global Inflammatory Bowel Diseases (IBD) Drug Market forecasts from 2019-2029 by Indication:
• Crohn’s Disease
• Ulcerative Colitis

• Global Inflammatory Bowel Diseases (IBD) Drug Market forecasts from 2019-2029 by Distribution Channel:
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

• Global Inflammatory Bowel Diseases (IBD) Drug Market forecasts from 2019-2029 by Drug Class:
• Biologics
• Aminosalicylates
• Antibiotics
• Corticosteroids
• Immunomodulators

Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2019-2029

• Revenue forecast from 2019-2029 for the selected leading products:
• Apriso
• Asacol
• Canasa/Salofalk
• Cimzia
• Entyvio
• Humira
• Lialda
• Pentasa
• Remicade
• Simponi
• Tysabri
• Uceris
• Xifaxan

• Revenue forecasts from 2019-2029 for these national markets segmented by indication, drug class and distribution channel:
• US
• Japan
• Germany, France, UK, Spain and Italy (EU5)
• Brazil, Russia, India and China (BRIC)

• Discussions on research and development, including drug candidates in these classes:
• Interleukin (IL) inhibitors
• Cell-adhesion molecule (CAM) inhibitors
• TNF-alpha inhibitors
• Stem cell therapies
• JAK inhibitors
• Toll-like receptor agonists

• Assessment of selected leading companies that hold major market shares in the inflammatory bowel diseases drug industry:
• AbbVie
• Allergan
• Biogen
• Celgene Corporation
• Gilead Sciences
• Janssen
• Novartis
• Pfizer
• Roche
• Takeda
• UCB Pharma S.A.

• Discussions on trends in the industry and assesses strengths and weaknesses, as well as opportunities and threats (SWOT). It also analyses social, technological, economic and political factors (STEP) that influence the IBD market. Moreover, this report discusses factors that drive and restrain the IBD market.

• Key Questions Answered by This Report:
• How is the inflammatory bowel disease drugs industry and market evolving?
• What is the technological and commercial potential of those IBD therapies from 2019?
• What sales values are possible at overall world, submarket, product and national levels?
• What are the market shares of its segments and how will they change to 2029?
• How much will those submarkets’ revenues expand from 2019 to 2029?
• Which medicines will dominate and how high can leading brands’ revenues go from 2019 to 2029? Which products will gain in sales and which will lose market shares?
• What forces stimulate and restrain that industry and market from 2019 to 2029?
• How will political and economic issues affect that overall sector and its submarkets?
• How will relative shares of national markets change by 2029, and which region will lead the world then? How high will leading national revenues go?
• Who form the leading companies, what do they offer, and what are their commercial prospects?

Visiongain’s study is intended for anyone requiring commercial analyses for the Global Inflammatory Bowel Diseases (IBD) Drug Market. You find data, trends and predictions.

Buy our report today Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2019-2029: Aminosalicylates, Antibiotics, Corticosteroids, Immunomodulators, Biologics, Crohn’s Disease, Ulcerative Colitis, Hospital Pharmacy, Online Pharmacy, Retail Pharmacy.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2019-2029


Download sample pages

Complete the form below to download your free sample pages for Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2019-2029


Latest Pharma news

Visiongain Publishes Generic Drugs Market Report 2020-2030

The 431-page report provides clear detailed insight into the generic drugs market. Discover the key drivers and challenges affecting the market.

03 July 2020

READ

Visiongain publishes Clinical Workflow Solutions Market Report 2020-2030

Where is the Clinical Workflow Solutions market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2030, assessing data, trends, opportunities and business prospects there.

03 July 2020

READ

Visiongain Publishes Clinical Trials Market Report 2020-2030

With the growing burden of rare diseases around the world, there has been a rise and advancement in the therapy development of these types of diseases. While the fact remains that over 90% of these diseases lack approval for treatment and the total number of terminal rare diseases to receive the first treatment every year remains low.

01 July 2020

READ

Visiongain Publishes Clinical Risk Grouping Solutions Market Report 2020-2030

The market growth is attributed to the growing adoption of big data and AI in data management and monitoring of clinical information in health care.

01 July 2020

READ

Categories

Category